Karyopharm Therapeutics (KPTI) Cash from Operations (2012 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Cash from Operations came in at 11828000.0 in Q4 2025, up 54.17% YoY from 7671910.94 in Q4 2024, and down 101.84% on a QoQ basis from 5860000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Cash from Operations (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Cash from Operations data on file, last reported at 11828000.0 in Q4 2025.
- Quarterly Cash from Operations rose 54.17% year-over-year to 11828000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 75369000.0 (up 40.88% YoY) and the FY2025 annual result came in at 75369000.0, up 40.88% from the prior year.
- Cash from Operations slipped to 11828000.0 in Q4 2025, from 5860000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 25475000.0 in Q4 2021 to a low of 59197000.0 in Q1 2022.
- A 5-year average of 27612400.0 and a median of 26326500.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2021 — Cash from Operations jumped 183.16% — and 2022, when it sank 205.37%.
- Tracing KPTI's Cash from Operations over 5 years: stood at 25475000.0 in 2021, then slumped by 205.37% to 26843000.0 in 2022, then soared by 30.76% to 18585000.0 in 2023, then tumbled by 38.88% to 25810000.0 in 2024, then soared by 54.17% to 11828000.0 in 2025.
- The last three Cash from Operations figures came in at 11828000.0 (Q4 2025), 5860000.0 (Q3 2025), and 18697000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.83 Mn |
| Dec 31, 2025 | -11.83 Mn |
| Sep 30, 2025 | -5.86 Mn |
| Sep 30, 2025 | -5.86 Mn |
| Jun 30, 2025 | -18.70 Mn |
| Jun 30, 2025 | -18.70 Mn |
| Mar 31, 2025 | -38.98 Mn |
| Mar 31, 2025 | -38.98 Mn |
| Dec 31, 2024 | -25.81 Mn |
| Dec 31, 2024 | -25.81 Mn |
| Sep 30, 2024 | -19.45 Mn |
| Sep 30, 2024 | -19.45 Mn |
| Jun 30, 2024 | -38.50 Mn |
| Jun 30, 2024 | -38.50 Mn |
| Mar 31, 2024 | -43.73 Mn |
| Mar 31, 2024 | -43.73 Mn |
| Dec 31, 2023 | -18.59 Mn |
| Dec 31, 2023 | -18.59 Mn |
| Sep 30, 2023 | -29.53 Mn |
| Sep 30, 2023 | -29.53 Mn |